Showing results (51-60 of 74) with videos related to
Sort By:
Pageof 8
Cancers|May 6, 2020
Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC PatientsElba Marin, Cristina Teixido, Elena Carmona-Rocha, et al.Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancerDavid Planchard, Jürgen Wolf, Benjamin Solomon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung CancerJordi Remon, Benjamin Besse, Santiago Ponce Aix, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2021
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE StudyFiona Blackhall, Kevin Jao, Laurent Greillier, et al.Cancer Cell|July 18, 2006
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancerBin-Bing S Zhou, Michael Peyton, Biao He, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2023
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I StudyLuis Paz-Ares, Stephane Champiat, W Victoria Lai, et al.Lung Cancer (Amsterdam, Netherlands)|June 12, 2022
Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) surveySara Pilotto, Alice Avancini, Jessica Menis, et al.Ecancermedicalscience|March 4, 2026
Oncology with common sense: beyond biologistic and pharmacological modelsRodrigo Lastra, Patricia Iranzo, Javier-David Benítez-Fuentes, et al.Plos One|May 6, 2009
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expressionRafael Rosell, Laia Perez-Roca, Jose Javier Sanchez, et al.The New England Journal of Medicine|August 21, 2009
Screening for epidermal growth factor receptor mutations in lung cancerRafael Rosell, Teresa Moran, Cristina Queralt, et al.Pageof 8